News|Articles|December 22, 2025

Ophthalmology in 2025: Year in Review

Catch up on the most impactful headlines in ophthalmology from all of 2025 with our Year in Review.

Plenty of major decisions from the US Food and Drug Administration (FDA) and key trial results have punctuated 2025 for ophthalmology, making it a wildly productive year for the industry. Everything from diabetic retinopathy (DR) to diabetic macular edema (DME) was addressed at some point, with crucial drugs like Susvimo and Acoltremon Ophthalmic Solution receiving approval to enter US markets. Treatment pipelines with Nanoscope and eSight also made significant progress this past year, as detailed in episodes of New Insight with Veeral Sheth, MD.

Related to this article

November 3rd, 2026

8 Nephrology Headlines You Missed in October 2026

Nephrology in October 2026: FDA approves ravulizumab for IgAN, plus ORIGIN 3, RAINIER, TELIGAN, and ATTACK data from Kidney Week.

October 30th, 2026

Voceryq Gains FDA Accelerated Approval for Recurrent Respiratory Papillomatosis

The plasmid DNA immunotherapy Voceryq gained FDA accelerated approval after 27% of RRP-001 patients needed no surgery for 12 months.

November 6th, 2026

Saroglitazar Resolves MASH Without Fibrosis Worsening: EVIDENCES X

In the phase 2b EVIDENCES X trial, saroglitazar 4 mg resolved MASH without worsening fibrosis in 39.1% of patients vs 13.7% with placebo at 52 weeks.

November 6th, 2026

Q&A: Discussing 2027 GOLD Report Updates in COPD, With David Singh, MD

Dave Singh, MD, reflects on 2027 GOLD report refinements, from mucus plugs and early COPD to biologics awaiting regulatory approval.

November 6th, 2026

Semaglutide Linked to Lower Liver Enzymes, Weight in Real-World MASH Data

Retrospective data show semaglutide 2.4 mg was linked to lower liver enzymes, weight, and HbA1c in MASH, including vs resmetirom in a real-world cohort.

November 6th, 2026

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Francesca Polverino, MD, PhD, explains how oxidized and reduced IL-33 drive mucus dysfunction and inflammation in COPD, and why mucus plugs matter.

November 6th, 2026

Triple Therapy More Than Doubles HBsAg Loss vs Peginterferon in HBV

Phase 2 ENHANCE and ENRICH data show BRII-179 plus elebsiran and peginterferon increased HBsAg loss in chronic HBV, with priming halving peginterferon use.

November 6th, 2026

Fazirsiran Reduces Liver Z-AAT Burden in AATD Liver Disease

Pooled phase 2 data show fazirsiran 200 mg cut intrahepatic Z-AAT by about 90% vs placebo in AATD liver disease, with stable lung function through the OLE.